Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1

July 23, 2024

— Pharma 1 anticipates filing UAE regulatory submission for Phexxi as a hormone-free contraceptive in Q3 2024 —

— UAE contraceptive drug market is projected to reach $185.1 million by 2030 —

Related news for (EVFM)

FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences’ “One and Done” Oral Treatment for Bacterial Vaginosis and Trichomoniasis
Evofem Biosciences to Present at Emerging Growth Conference
Windtree Therapeutics Strikes Deal to Source PHEXXI, Signaling Revenue-Driven Pivot
Evofem Biosciences Announces Financial Results for the Third Quarter of 2024
Evofem Biosciences Announces Financial Results for the Second Quarter of 2024

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.

Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1

Related news for (EVFM)

Follow Us on Social Media

Sign Up for Our Newsletter

Related news for (EVFM)

Palisade’s Blockbuster Raise and Kraig’s Next-Gen Textiles Light Up the Morning

From EVs to Bitcoin Treasuries: Small-Caps Set the Tone Ahead of the Bell

Morning Market Movers: Disruption, Defense & AI Dominate the Headlines

C4 Therapeutics Teams Up with Pfizer on New Myeloma Combo Trial

From Real Estate Reinvention to Biotech Breakouts- These Are the Stocks to Watch into the Close

Follow Us on Social Media

Sign Up for Our Newsletter